Researchers at the University of Eastern Finland and their international collaborators have identified key developmental and molecular differences between the two main subtypes of chronic lymphocytic ...

The chronic phase is the first and most treatable phase of chronic myeloid leukemia. It is characterized by a low percentage of abnormal cells in the blood and bone marrow. With treatment, most people ...

Leukemia and lymphoma are cancers that affect the blood or bone marrow. Fifteen percent of people with leukemia have chronic myeloid leukemia (CML), which has seen a 55% jump in new cases over the ...

This systematic review focusing on the targeted therapy era found solid associations between measurable residual disease (MRD) and clinical outcomes in patients with chronic lymphocytic leukemia.

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical ...

Chronic lymphocytic leukemia (CLL) treatment options depend on your diagnosis. In earlier stages, “watchful waiting” may be recommended. More advanced CLL may require a combination of therapies.

Propensity-matched TriNetX cohorts of ibrutinib and acalabrutinib recipients showed atrial fibrillation incidence rising with ...

Alert FDA Approves Third-Ever Drug for Lupus Nephritis Obinutuzumab (Gazyva) is the first drug to be approved for lupus nephritis since the approvals of belimumab (Benlysta) in 2020 and voclosporin ...

Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic blood cancer, potential treatments for Richter transformation, and ...